HPV16 Positive clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
at UCSD UCSF